Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 5/20 | 0.44 |
| ▸ | LCK | P06239 | 3/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 5/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.35 |
| ▸ | CDK2 | P24941 | 3/20 | 0.35 |
| ▸ | CDK9 | P50750 | 3/20 | 0.35 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30595879 | 1.00 | SYK (0.44) | SYKLCKMAPK8CCNT1CCNE1 | |
| SCHEMBL30595902 | 0.91 | MAPK8 (0.41) | SYKLCKMAPK8CCNT1CCNE1 | |
| SCHEMBL26075404 | 0.91 | MAPK8 (0.41) | SYKLCKMAPK8CCNT1CCNE1 | |
| SCHEMBL29537017 | 0.87 | MET (0.45) | CCNT1CCNE1CDK2CDK9 | |
| SCHEMBL25421662 | 0.87 | MET (0.45) | CCNT1CCNE1CDK2CDK9 | |
| SCHEMBL30590720 | 0.85 | EGFR (0.50) | — | |
| SCHEMBL26074894 | 0.85 | EGFR (0.50) | — | |
| Formic Acid SCHEMBL25423830 | 0.84 | SCN9A (0.39) | SYKCCNT1CCNE1CDK2CDK9 | |
| Formic Acid SCHEMBL29536657 | 0.84 | SCN9A (0.39) | SYKCCNT1CCNE1CDK2CDK9 | |
| Formic Acid SCHEMBL30595851 | 0.83 | EGFR (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORP (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORP (US) | 2023-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ERBB2, ERBB3, ERBB4 | SYK 92/4885LCK 55/4885MAPK8 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.